Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 14, 2014, Pages 2071-2079

  Han, Leo ^a   Jensen, Jeffrey T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Combined oral contraceptive; Cycle regulation; Drospirenone; Ethinyl estradiol; Flexible extended regimen; Flexyess; Menstrual bleeding; Oral contraceptive pills

Indexed keywords

DROSPIRENONE; ETHINYLESTRADIOL; SEX HORMONE BINDING GLOBULIN; ANDROSTANE DERIVATIVE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CHOLESTASIS; CONTRACEPTION; DIARRHEA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; FOLLOW UP; HEADACHE; HUMAN; MEDICATION COMPLIANCE; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); NODULAR HYPERPLASIA; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL (TOPIC); RHINOPHARYNGITIS; STEADY STATE; UTERUS MYOMA; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; FEMALE; MENSTRUATION;

ANDROSTENES; CLINICAL TRIALS AS TOPIC; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUATION;

EID: 84907059434     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.949237     Document Type: Article

References (40)

1. Bayer Healthcare Pharmaceuticals. Yaz prescribing information. 2012. Available from: http://labeling. bayerhealthcar e.com/html/products/pi/fhc/YAZ-PI.pdf?WT.mc-id=www.berlex. com [Cited 5 May 2014]
2. Warner Chilcott Co. Lo Loestrin Fe prescribing information. 2012. Available from: http://www.loloestrin.com/docs/pi-loloestrinfe.pdf [Cited 5 May 2014]
3. Teva Women's Health, Inc. Mircette prescribing information. 2012. Available from: http://dailymed. nlm.nih.gov/dailymed/lookup.cfm? setid=997a8511-357b-42b7-aa4c-00895bed1e10 [Cited 6 May 2014]
4. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117(1):33-40
5. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78(1):16-25
6. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006;74(5):359-66
7. Anderson FD, Feldman R, Reape KZ. Endometrial e ffects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception 2008;77(2):91-6 . Primary efficacy and safety study of fixed extended regimen of ethinyl estradiol (EE)/LNG
8. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68(2):89-96
9. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74(6):439-45
10. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101(4):653-61
11. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004;70(5):359-63
12. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards lon g-cycle treatment with oral contraceptives. Contraception 2004;69(1):37-42
13. American College of Obstetricians and Gynecologists, Practice Bulletin 15 Premenstrual Syndrome: clinical management guidelines for obstetricians-gynecologists, 2000, 95, 1-9.
14. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59(6):357-62
15. Pharmaceuticals BH. Clyk product descr iption. 2011. Available from: http://www.hcpceurope. net/cms/upload/Comp-enh-pack/gr/Bayer-Description.pdf [Cited 23 April 2014]
16. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a l ow-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61(2):105-11
17. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contr aceptive containing an antimineralocorticoid progestogen, drospirenone, on the reninaldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80(6):1816-21
18. Berlex, Inc. Yasmin (drospirenone and ethinyl estradiol) prescribing information. 2005. Available from: http://www.berlex.com/html/products/pi/fhc/Yasmin-PI.pdf?WT.mc-id=berlex.com [Cited 4 May 2014]
19. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005;8(Suppl 3):4-12
20. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother 2007;8(7):989-99
21. Reif S, Snelder N, Blode H. Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic anal ysis from a randomised Phase III study. J Fam Plann Reprod Health Care 2013;39(2):e1
22. DiLiberti CE, O'Leary CM, Hendy CH, et al. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen. Contraception 2011;83(1):55-61
23. Klipping C, Duijkers I, Fortier MP, et al. Contraceptive efficacy and tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012;38(2):73-83
24. Klipping C, Duijkers I, Fortier MP, et al. Long-term tol erability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012;38(2):84-93
25. Jensen JT, Garie SG, Trummer D, Elliesen J. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an openlabel, three-arm, active-controlled, multicenter study. Contraception 2012;86(2):110-18
26. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004;70(3):191-8
27. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142, 475 women-years of observation. Contraception 2007;75(5):344-54
28. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75(5):328-36
29. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65(3):187-96
30. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890
31. Lidegaard O, N ielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001-9. BMJ 2011;343:d6423
32. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
33. Jick SS, Hernandez RK. Risk of nonfatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control st udy using United States claims data. BMJ 2011;342:d2151
34. Parkin L,Sharples K,Hernandez RK,Jick SS, Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database, BMJ, 2011, 342, d2139.
35. Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the probl em of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care 2012;38(1):2-6
36. Grimes DA. Epidemiologic research using administrative databases: garbage in, garbage out. Obstet Gynecol 2010;116(5):1018-19
37. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenonecontaining combined oral contraceptives: final results from the Internationa l Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014;89(4):253-63
38. European Medical Agencies. Assessment report for combined hormonal contraceptives containing medicinal products. London, England; 2014
39. Jones JM, Mosher W, Daniels K. Current contraceptive use in the United States: 2006-2010, and changes in patterns of use since 1995. National Health Statistics Reports. 2012. Available from: http://www.cdc. gov/nchs/data/nhsr/nhsr060.pdf [Cited 20 April 2014]
40. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone w ithdrawal symptoms. Obstet Gynecol 1997;89(2):179-83